The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections | Zendy

Pranita D. Tamma | Zendy; Jesús RodríguezBaño | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections

Author(s) -

Pranita D. Tamma,

Jesús RodríguezBaño

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix034

Subject(s) - cefepime , medicine , tazobactam , piperacillin , piperacillin/tazobactam , carbapenem , ceftazidime , antibiotics , ceftazidime/avibactam , cephalosporin , intensive care medicine , beta lactamase inhibitors , beta lactamase , microbiology and biotechnology , imipenem , biology , antibiotic resistance , escherichia coli , pseudomonas aeruginosa , bacteria , biochemistry , gene , genetics

The continued rise in infections caused by extended-spectrum β-lactamase (ESBL)-producing pathogens is recognized globally as one of the most pressing concerns facing the healthcare community. Carbapenems are widely regarded as the antibiotics of choice for the treatment of ESBL-producing infections, even when in vitro activity to other β-lactams has been demonstrated. However, indiscriminant carbapenem use is not without consequence, and carbapenem overuse has contributed to the emergence of carbapenem-resistant Enterobacteriaceae. The use of non-carbapenem β-lactams for the treatment of ESBL infections has yielded conflicting results. In this review, we discuss the available data for the use of cephamycins, cefepime, piperacillin-tazobactam, ceftolozane-tazobactam, and ceftazidime-avibactam for the treatment of ESBL infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research